PDE III Inhibitors Supplement β-Agonists in Acute Cardiac Insufficiency


    loading  Checking for direct PDF access through Ovid

Abstract

IN BRIEFSelective phosphodiesterase type III (PDE III) inhibitors may be most useful as add-on therapy in patients with acute cardiac insufficiency. This may be justified when the response to β-agonists or sodium nitroprusside is inadequate or when tolerance develops to the effects of β-agonists.Failure of conventional therapy in this situation may be fatal. Thus, it appears justified to use them in such a critical situation despite there being limited data regarding this use of PDE III inhibitors.Local availability and acquisition cost are likely to influence the choice of PDE III inhibitor.Orally administered PDE III inhibitors cannot be recommended to treat chronic heart failure as they increase mortality compared with placebo.

    loading  Loading Related Articles